Blog

Finding flexibility in a resource limited world: Online presentation

Time and resource optimization are top-of-mind for many clinical labs working with NGS. As a resource for clinical researchers and labs, we revisit this presentation on panel evaluation. In this presentation, initially shared as a corporate workshop at AMP 2019, Cynthia Schandl, MD, PhD and Julie Hirschhorn, PhD evaluate the flexibility, affordability, and ease-of-use of …

Finding flexibility in a resource limited world: Online presentation Read More »

Four people smile out of the screen from their lab stations.

The complexity of the NGS process, compounded by sample processing, results in unique challenges for clinical oncology laboratories

Increasingly, clinical samples of all types are being analyzed with the goal of matching patients to target therapies. In the summer of 2017, Thermo Fisher received the first FDA companion diagnostic test approval for multiple non-small cell lung cancer (NSCLC) therapies, while Foundation Medicine received FDA approval for their FoundationFocus CDxBRCA as a companion diagnostic for an ovarian cancer …

The complexity of the NGS process, compounded by sample processing, results in unique challenges for clinical oncology laboratories Read More »

Top 5 reasons to go custom with Pillar Biosciences in graphic font

5 reasons to go custom with your next sequencing panel

Off-the-shelf next-generation sequencing (NGS) panels save on sequencing costs by targeting specific genes, and the smaller resulting datasets are easier to analyze. The catch is, panels are limited to a defined set of genetic targets. This one-size-fits all approach is not well-suited to the cancer research community’s rapid pace of discovery. Custom panels, on the …

5 reasons to go custom with your next sequencing panel Read More »

a graphic that reads "Garbage in, Greatness out" next to a photo of a tumor sample embedded in parafin wax for analysis

Garbage in, greatness out: making the most of FFPE samples

The cancer research community relies on formalin-fixed samples, but the quality of these samples degrades over time. Sequencing data from partially degraded samples is plagued with artifacts. To address this “garbage in, garbage out” problem, Pillar Biosciences has developed a suite of tools that help sort actual variants from artifactual variants in low quality samples. …

Garbage in, greatness out: making the most of FFPE samples Read More »

Helen Fernandes at Columbia University uses Pillar NGS panel as new tumor sequencing workhorse

Meet SLIMamp: Columbia University’s new tumor sequencing workhorse

Next generation sequencing (NGS) is a powerful diagnostic tool for identifying tumor variants. Tumor sequencing workflows often rely on off-the-shelf panels, which allow for multiplexed amplification of known cancer mutational “hotspots”. These panels are diagnostically useful, but they can’t keep pace with the cancer research community’s diligent uncovering of new, previously unknown hotspots, genes, and …

Meet SLIMamp: Columbia University’s new tumor sequencing workhorse Read More »

Social media graphic advertising the AMP 2018 Pillar Workshop speaker, Helen Fernandes, PhD.

Workshop: Single-vial amplification-based NGS to interrogate variants in tumors with limited diagnostic material

Helen Fernandes, PhD, Co-director of Genomic Oncology at Columbia University, presented a talk on October 31, 2018 during the Corporate Workshop Day at the 2018 Association for Molecular Pathology (AMP) Annual Meeting in San Antonio, Texas.  Click below to watch Dr. Fernandes’ talk:   Click here In her talk, titled “Single-vial amplification-based NGS with rapid …

Workshop: Single-vial amplification-based NGS to interrogate variants in tumors with limited diagnostic material Read More »

Scroll to Top